InnoCan Pharma Corporation (CSE: INNO)

Market Cap	65.71M
Revenue (ttm)	33.38M
Net Income (ttm)	-5.94M
Shares Out	285.69M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.240
Previous Close	0.240
Day's Range	0.230 - 0.240
52-Week Range	0.185 - 0.410
Beta	3.01
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2023, InnoCan Pharma's revenue was $13.66 million, an increase of 433.69% compared to the previous year's $2.56 million. Losses were -$4.70 million, 24.9% more than in 2022.

Financial numbers in USD